Login to Your Account

Biocon, Quark move forward on trials for NAION treatment

By T.V. Padma
Staff Writer

Tuesday, June 28, 2016

NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription